Hans Wigzell - Karolinska Development Insider

KDEV -- Sweden Stock  

SEK 8.86  0.42  4.53%

Dr. Hans Wigzell, M.D., Ph.D. was Chairman of the Board of Directors at Karolinska Development AB since December 29, 2017. He was Independent Director of the Company since 2006. He no longer serves as Independent Chairman of the Board effective as of September 30, 2013. He is also Chairman of Rhenman Partner Asset Management AB and Cadila Pharmaceuticals Sweden Aktieboag, and Member of the Boards of Sarepta Therapeutics Inc. and RaySearch Laboratories AB. He is Member of The Royal Swedish Academy of Engineering Sciences and of the Royal Swedish Academy of Sciences. His previous assignments include, among others, President of Karolinska Institutet Nobel Committee, and President of Karolinska Institutet and Director General of the Smittskyddsinstitutet. He is Professor Emeritus of Immunology and Medical Doctor.
Age: 79  Chairman Since 2017  Ph.D    
46 8 52 48 60 70  http://www.karolinskadevelopment.com

Management Efficiency

The company has return on total asset (ROA) of (4.09) % which means that it has lost $4.09 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 119.32 % meaning that it generated $119.32 on every $100 dollars invested by stockholders.
The company has accumulated 391.46 M in total debt with debt to equity ratio (D/E) of 158.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Karolinska Development AB has Current Ratio of 16.14 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Entity Summary

Karolinska Development AB is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. Karolinska Development AB was founded in 2003 and is headquartered in Stockholm, Sweden. Karolinska Development operates under Pharmaceuticals And Biosciences classification in Sweden and traded on Stockholm Stock Exchange. It employs 7 people.Karolinska Development AB (KDEV) is traded on Stockholm Stock Exchange in Sweden. It is located in Tomtebodav?gen 23 A and employs 7 people.

Karolinska Development AB Leadership Team

Hans Wigzell, Independent Chairman of the Board
Elisabet Gimbringer, Controller
Carl Sundberg, Director
Magnus Persson, Director
Jim Heusden, CEO
Maria Ferm, Executive Assistant
HansOlov Olsson, Director
Theresa Tse, Director
Viktor Drvota, Chief Investment Officer
Eva Montgomerie, Head of Accounting
Michael Owens, Controller
Yan Cheng, President Asia
Ulf Richenberg, General Counsel
Niclas Adler, Director
Tse Ping, Director
Christian Tange, CFO
Daniel Bolanowski, Business Analyst
Terje Kalland, Chief Scientific Officer
Vladimir Artamonov, Independent Director
Felicia Rittemar, Analyst
AnnSofie Sternas, Vice President IPR
Anders Harfstrand, Director
Bo Hansen, Chairman of the Board
Fredrik Jarrsten, CFO
Khalid Islam, Director
Gunilla Ekstrom, Vice President - Operations
Henrijette Richter, Director

Stock Performance Indicators

Current Sentiment - KDEV

Karolinska Development AB Investor Sentiment
Macroaxis portfolio users are evenly split in their trading attitude regarding investing in Karolinska Development AB. What is your trading attitude regarding investing in Karolinska Development AB? Are you bullish or bearish?
50% Bullish
50% Bearish

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Transaction History module to view history of all your transactions and understand their impact on performance.